WO1992004015A3 - REGULATION DE LA PROLIFERATION DE LYMPHOCYTES T VIA UN NOUVEAU RECEPTEUR, LE 5HT1a - Google Patents

REGULATION DE LA PROLIFERATION DE LYMPHOCYTES T VIA UN NOUVEAU RECEPTEUR, LE 5HT1a Download PDF

Info

Publication number
WO1992004015A3
WO1992004015A3 PCT/US1991/006176 US9106176W WO9204015A3 WO 1992004015 A3 WO1992004015 A3 WO 1992004015A3 US 9106176 W US9106176 W US 9106176W WO 9204015 A3 WO9204015 A3 WO 9204015A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell proliferation
regulation
novel
5ht1a receptor
proliferation via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/006176
Other languages
English (en)
Other versions
WO1992004015A2 (fr
Inventor
Thomas Martin Aune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Priority to JP3517820A priority Critical patent/JPH06503816A/ja
Publication of WO1992004015A2 publication Critical patent/WO1992004015A2/fr
Publication of WO1992004015A3 publication Critical patent/WO1992004015A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Le procédé décrit qui permet de réguler la prolifération de lymphocytes T activés présentant un récepteur de type 5HT1a, consiste à introduire une quantité suffisante d'agents agonistes ou antagonistes dans le but soit d'augmenter soit de diminuer la prolifération des lymphocytes T. Le moyen utilisé comme base de régulation de la prolifération des lymphocytes T peut être: (1) le récepteur 5HT, (2) l'inhibition de la synthèse de la sérotonine, et/ou (3) la stimulation par la sérotonine des sous-populations CD8+ de lymphocytes T activés.
PCT/US1991/006176 1990-09-04 1991-09-04 REGULATION DE LA PROLIFERATION DE LYMPHOCYTES T VIA UN NOUVEAU RECEPTEUR, LE 5HT1a Ceased WO1992004015A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3517820A JPH06503816A (ja) 1990-09-04 1991-09-04 新規な５ＨＴ１ａ受容体を介するＴ細胞増殖の調節

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57871090A 1990-09-04 1990-09-04
US578,710 1990-09-04

Publications (2)

Publication Number Publication Date
WO1992004015A2 WO1992004015A2 (fr) 1992-03-19
WO1992004015A3 true WO1992004015A3 (fr) 1992-04-16

Family

ID=24313971

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1991/006176 Ceased WO1992004015A2 (fr) 1990-09-04 1991-09-04 REGULATION DE LA PROLIFERATION DE LYMPHOCYTES T VIA UN NOUVEAU RECEPTEUR, LE 5HT1a
PCT/US1991/006175 Ceased WO1992004014A2 (fr) 1990-09-04 1991-09-04 Regulation de la proliferation de cellules neoplasiques par l'intermediaire d'un nouveau recepteur 5ht1a

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006175 Ceased WO1992004014A2 (fr) 1990-09-04 1991-09-04 Regulation de la proliferation de cellules neoplasiques par l'intermediaire d'un nouveau recepteur 5ht1a

Country Status (5)

Country Link
EP (2) EP0555231A1 (fr)
JP (2) JPH06500775A (fr)
AU (2) AU8848291A (fr)
CA (2) CA2090689A1 (fr)
WO (2) WO1992004015A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461054A (en) * 1993-12-09 1995-10-24 Bayer Aktiengesellschaft Anthracene-spiro-pyrrolindines
US5411960A (en) * 1993-12-09 1995-05-02 Bayer Aktiengesellschaft Substituted pyrroloanthracenes and -diones
US5409932A (en) * 1993-12-09 1995-04-25 Bayer Ag Piperazine-substituted pyrroloanthracenes
WO1996001106A1 (fr) * 1994-07-06 1996-01-18 Bo Arne Hofmann Emploi d'agents pharmaceutiques pour attenuer ou traiter la dysfonction immunitaire liee a l'infection par le vih ou des virus associes
AU2880595A (en) * 1994-07-06 1996-01-25 Bo Arne Hofmann Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
EP0813878B1 (fr) * 1996-06-17 2002-02-06 Mitsubishi Chemical Corporation Agent pour accélérer la lacrimation contenant un ligand de la sérotonine, particuliérement un composé aminoalkoxybibenzyle
AU2002305123B2 (en) 2001-03-30 2006-10-05 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
CA2683316A1 (fr) * 2007-04-13 2009-02-19 Southern Research Institute Agents anti-angiogeniques et procedes d'utilisation
AU2021337864A1 (en) * 2020-09-02 2023-05-04 Yztherapeutic Performance Ltd. Cellular composition for treatment of diseases, disorders or conditions and method of use
CN113599370B (zh) * 2021-08-03 2023-12-08 复旦大学附属肿瘤医院 8-oh-dpat及其衍生物在制备抗肿瘤药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489108B1 (fr) * 1989-08-21 1996-03-13 Beth Israel Hospital Association Utilisation des derivatives de spiperone pour immunosuppresion

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Eur. J. Pharmacol., vol. 170, no. 1/2, October 1989, Elsevier Science Publishers B.V., Amsterdam (NL), M. Pranzatelli et al.: "Identification of 5-HT1A recognition sites in human ganglioneuroblastoma", pages 127-128, see the whole article *
J. Immunol., vol. 145, no. 6, 15 September 1990, Baltimore (US), T. Aune et al.: "Serotonin-activated signal transduction via serotonin receptors on Jurkat cells", pages 1826-1831, see the whole article *
N. Engl. J. Med., vol. 277, no. 21, 23 November 1967, Boston (US), K. Engelman et al.: "Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome", pages 1103-1108, see page 1108, lines 13-32 *
Proc. Natl. Acad. Sci, USA, vol. 82, no. 2, January 1985, Washington DC, (US) R. Todd et al.: "Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child", pages 612-616, see the abstract *

Also Published As

Publication number Publication date
JPH06503816A (ja) 1994-04-28
JPH06500775A (ja) 1994-01-27
WO1992004014A3 (fr) 1992-05-14
WO1992004015A2 (fr) 1992-03-19
CA2090688A1 (fr) 1992-03-05
AU8848291A (en) 1992-03-30
EP0555231A1 (fr) 1993-08-18
WO1992004014A2 (fr) 1992-03-19
AU8499891A (en) 1992-03-30
CA2090689A1 (fr) 1992-03-05
EP0547172A1 (fr) 1993-06-23

Similar Documents

Publication Publication Date Title
SG48225A1 (en) Styryl-substituted heteroaryl compounds which inhibit for receptor tyrosine kinase
MD1616F2 (en) Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment
WO1992004015A3 (fr) REGULATION DE LA PROLIFERATION DE LYMPHOCYTES T VIA UN NOUVEAU RECEPTEUR, LE 5HT1a
MY118556A (en) Catalytic composition suitable for the fischer-tropsch process
AU558375B2 (en) 6-(7-)-oxy-trans-1,2,3,4,4a,5,10,10a-octahydrobenzo (g)quinolines
ES8801789A1 (es) Un procedimiento para la preparacion de derivados de indol
AU5165393A (en) Substituted benzylaminoquinuclidines as substance p antagonists
CA2137793A1 (fr) Cristallisation de m-csf
AU560028B2 (en) Pyridine-n-oxide derivatives
AU9648098A (en) Adenosine a3 receptor antagonists
HU9203515D0 (en) Method for producing neuron protective indolones, their analogous derivatives and pharmaceutical preparatives containing these compounds
ATE238771T1 (de) Herstellungsverfahren von löslichen verabreichungssystemen unter verwendung von flüchtigen salzen
AU1208397A (en) Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
EP0354777A3 (fr) Dérivés du 3-(4-pipéridine)-5-(2-sulfonylaminoéthyl)-indole
EP0351112A3 (fr) Composé photochromique, procédé de préparation, son application et composition photochromique le contenant
MY113266A (en) New indol derivatives derivatives with high affinity 5-ht1a receptor.
TW248566B (fr)
AU2999684A (en) Substituted 2-(monoannelated (3,4-, 4,5- and 5,6-) pyridylalkylenesulfinyl)-benzimidazoles
DK616084A (da) Inaktivt bindemiddel paa basis af polycaprolacton til et gennem munden indgiveligt laegemiddel samt fremgangsmaade til fremstilling af en blanding omfattende bindemidlet
AU2736495A (en) Agonists and antagonists of the nicotinic acetylcholine receptors of insects to control endoparasites
ES8800214A1 (es) Procedimiento para preparar derivados de bencimidazol substituidos
CY2039B1 (en) 5-HT 1-like receptor agonist for rectal administration
AU1548592A (en) Cyclopentenes
EP0255717A3 (fr) Dérivés de gangliosides et leur procédé de préparation
ES8600740A1 (es) Un procedimiento para la preparacion de nuevos derivados de isoindol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991918533

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2090689

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991918533

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991918533

Country of ref document: EP